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Background: Current management strategies attempt to di-
agnose rheumatoid arthritis (RA) at an early stage. Trans-
cription profiling is applied in the search for biomarkers for 
detecting early-stage disease. Even though gene profiling 
has been reported using several animal models of RA, most 
studies were performed after the development of active ar-
thritis, and conducted only on the peripheral blood and joint. 
Therefore, we investigated gene expression during the initial 
phase of collagen-induced arthritis (CIA) before the arthritic 
features developed in the thymus in addition to the periph-
eral blood and synovium. Methods: For gene expression anal-
ysis using cDNA microarray technology, samples of thymus, 
blood, and synovium were collected from CIA, rats immu-
nized only with type II collagen (Cll), rats immunized only 
with adjuvant, and unimmunized rats on days 4 and 9 after 
the first immunization. Arrays were scanned with an Illumina 
bead array. Results: Of the 21,910 genes in the array, 1,243 
genes were differentially expressed at least 2-fold change in 
various organs of CIA compared to controls. Among the 
1,243 genes, 8 encode T-cell receptors (TCRs), including 
CD3ζ, CD3δ, CD3ε, CD8α, and CD8β genes, which 
were down-regulated in CIA. The synovium was the organ in 
which the genes were differentially expressed between CIA 
and control group, and no difference were found in the thy-
mus and blood. Further, we determined that the differential 
expression was affected by adjuvant more than Cll. The dif-
ferential expression of genes as revealed by real-time 
RT-PCR, was in agreement with the microarray data. 
Conclusion: This study provides evidence that the genes en-
coding TCRs including CD3ζ, CD3δ, CD3ε, CD8α, and 
CD8β genes were down-regulated during the initial phase of 
CIA in the synovium of CIA. In addition, adjuvant played a 
greater role in the down-regulation of the CD3 complex com-
pared to CII. Therefore, the down-regulation of TCR gene ex-
pression occurred dominantly by adjuvant could be involved 
in the pathogenesis of the  early stage at CIA.
[Immune Network 2011;11(5):258-267]
INTRODUCTION
Rheumatoid  arthritis  (RA)  is  characterized  by  a  chronic  in-
flammatory  process,  which  primarily  involves  the  synovial 
membrane and is typically associated with serologic evidence 
of systemic autoimmunity, culminating in loss of joint function 
(1). The presence of auto-antibodies, such as rheumatoid fac-
tor (RF) and anti-cyclic citrullinated peptide (anti-CCP) anti-
bodies, can precede the clinical manifestations of RA by many 
years (2). Therefore, it is recommended that effective therapy 
be initiated as soon as autoimmune abnormalities appear (3); 
however, there are many unanswered questions regarding the 
pre-clinical stages of RA. The central questions relate to the 
factors that serve to initiate, amplify, and mature the immune 
responses in RA. It is difficult to investigate the molecular fea-
tures in patients with RA before the onset of clinical symp-
toms,  which  is  possible  in  animal  models.Gene Expression Profile of CIA
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    Collagen-induced arthritis (CIA) has been used to study the 
basic mechanisms of autoimmune arthritis because of the clin-
ical,  immunologic,  histologic,  and  genetic  similarity  to  RA 
(4-6). In this model, native type-II collagen (CII), when pre-
sented with an adjuvant, predictably and reproducibly precip-
itates a chronic inflammatory arthritis in the joints of genet-
ically-susceptible animals. The development of CIA is thought 
to depend on T cells, and disease susceptibility is linked to 
the major histocompatibility complex (MHC) (7). CII-specific 
CD4+T cells have been reported to be fundamental in the ini-
tiation  and  perpetuation  of  CIA  (8,9).  Recently,  abatacept, 
which targets T-cell modulation via the co-stimulatory CD80/ 
CD86:CD28  pathway,  exemplifies  the  rationale  and  efficacy 
of  using  T-cell  modulation  as  a  therapeutic  approach  (10). 
Therefore,  the  abnormality  in  T  cell-related  immunity  plays 
a  role  in  the  pathogenesis  of  RA.  In  addition,  the  primary 
mechanism leading to tolerance to self-antigens is the dele-
tion of self-reactive T cells in the thymus through the mecha-
nism by which T cells with a high affinity for self-peptides 
undergo the active induction of apoptosis. Autoimmune ar-
thritis in various animal models can be attributed to a defect 
in T cell selection within the thymus (11-13). Since, we ques-
tioned where and when T cell immunity dysregulation occurs, 
we investigated the gene expression of T cell-related mole-
cules, in the thymus, peripheral blood and synovium during 
the initiation phase of CIA using cDNA microarray technology 
followed  by  validation  using  real-time  PCR.
MATERIALS AND METHODS 
Animals
A d u l t  f e m a l e  L e w i s  r a t s  ( 7  w e e k s  o l d )  w e i g h i n g  a p p r o x -
imately 150 g were obtained from Harlan (Indianapolis, IN, 
USA), housed under standard conditions, and given free ac-
cess to food and water. The rats were adapted to the new 
conditions  for  at  least  7  days  before  the  initiation  of  the 
studies. All experiments were conducted in accordance with 
the animal care guidelines of the National Institutes of Health 
and the Korean Academy of Medical Sciences. This study was 
approved by the Eulji University Animal Institutional Review 
Board.
Rat CIA model
Chicken  CII  (Sigma-Aldrich,  St.  Louis,  MO,  USA)  was  dis-
solved  in  0.05  M  acetic  acid  to  a  final  concentration  of  4 
mg/ml. CII emulsified in incomplete Freundʼs adjuvant (IFA) 
was  homogenized  at  a  1：1  ratio  using  a  PowerGen  35 
(Fisher Scientific, Pittsburgh, PA, USA). For the induction of 
C I A ,  r a t s ,  8  w e e k s  o l d  ( n＝3  per  group),  were  immunized 
intradermally at the base of the tail with 0.2 ml of the emul-
sion on day 0, followed by one-half volume of each on day 
7.  Another  group  of  rats  were  immunized  only  with  and 
equivalent volume of  IFA, only with CII on the same days. 
Non-immunized  rats  were  used  of  control  group.
    Arthritis was assessed daily, and inflammation was scored, 
as described by Nanakumar and co-workers (14). In our pre-
vious  study,  the  induction  ratio  of  CIA  was  ＞86%. 
    Each  experimental  condition  was  reproduced  three  times 
(RNA isolation, probe preparation, and independent hybrid-
i za ti on ),  an d  ea ch  re pl ic at e c o nt ai ne d  RN A s am ple s p oo le d 
f r o m  t h r e e  a n i m a l s .
    For gene expression analysis, the sample was collected on 
days 0 (control), 4, and 9. Sample tissues from three rats were 
collected at each time point. Blood was collected through the 
postcaval  vein  from  each  animal.  Synovium  was  collected 
from  the  posterior  knee  joint.  Samples  were  treated  with 
RNAlater (Ambion, Austin, TX, USA) to prevent RNA degra-
dation. 
RNA preparation
Total  RNA  was  extracted  using  Trizol  (Invitrogen  Life 
Technologies, Carlsbad, CA, USA) and purified using RNeasy 
columns (Qiagen, Valencia, CA, USA), according to the man-
ufacturerʼs  protocol.  After  processing  with  DNase  digestion 
and clean-up procedures, the RNA samples were quantified, 
aliquotted, and stored at －80
oC until use. For quality control, 
RNA  purity  and  integrity  were  evaluated  by  denaturing  gel 
electrophoresis,  the  OD  260/280  ratio,  and  analyzed  on  an 
Agilent  2100  Bioanalyzer  (Agilent  Technologies,  Palo  Alto, 
CA,  USA).
Labeling and purification
Total  RNA  was  amplified  and  purified  using  the  Ambion 
Illumina RNA amplification kit (Ambion) to yield biotinylated 
cRNA,  according  to  the  manufacturerʼs  instructions.  Briefly, 
550 ng of total RNA was reverse-transcribed to cDNA using 
a T7 oligo (dT) primer. Second-strand cDNA was synthesized, 
in vitro-transcribed, and labeled with biotin-NTP. After purifi-
cation, the cRNA was quantified using a ND-1000 spectropho-
tometer  (NanoDrop,  Wilmington,  DE,  USA). Gene Expression Profile of CIA
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Table I. Primer sequences used in real-time PCR
Gene Forward Reverse
CD8α 5’-GGCCAGGAGGTGAAGCTAAC-3’ 5’-GCTAGGCTTGCTCAGGGTGA-3’
CD8β 5’-CATGGATGTGAAGCCAGAGG-3’ 5’-ATGAAGTGAATCCGGGCTCT-3’
CD3δ 5’-GTGCCAGAACTGTGTGGAGC-3’ 5’-TGGCCTGCAAAGCAGTAGAC-3’
CD3ε 5’-ATGCAGTGGAACGCTTTCTG -3’ 5’-GAGGGCACGTCAGCTCTACG-3’
CD3ζ 5’-GCTGCTTACCTTCAGGACCC-3’ 5’-GCTGAGACCCTGGTAAAGGC-3’
Hybridization and data export
Seven  hundred  fifty  nanograms  of  labeled  cRNA  samples 
were hybridized to each Rat-12 expression bead array for 16
∼18 h at 58
oC, according to the manufacturerʼs instructions 
(Illumina Inc., San Diego, CA, USA). Detection of array sig-
nals  was  carried  out  using  Amersham  fluorolink  streptavi-
din-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK), ac-
cording to the bead array manual. Arrays were scanned with 
an Illumina bead array Reader confocal scanner, according to 
the manufacturerʼs instructions. Array data export processing 
and  analysis  was  performed  using  Illumina  BeadStudio.
Raw data preparation and statistical analysis
The  quality  of  hybridization  and  overall  chip  performance 
were monitored by visual inspection of internal quality con-
trol  checks  and  the  raw  scanned  data.  Raw  data  were  ex-
tracted  using  the  software  provided  by  the  manufacturer 
(BeadStudio v. 3.3.0). Array data were filtered by a detection 
p-value＜0.05 (similar to signal-to-noise) in at least 50% of 
the samples. We applied a filtering criterion for data analysis; 
a higher signal value was required to obtain a detection p-val-
ue＜0.05. The selected gene signal value was transformed by 
logarithm and normalized by the quantile method. Compara-
tive analyses were carried out using a |fold|＞2. Hierarchical 
cluster  analysis  was  performed  using  complete  linkage  and 
Euclidean distance as a measure of similarity. All data analy-
ses  and  visualization  of  differentially-expressed  genes  were 
conducted using ArrayAssist
® (Stratagene, La Jolla, CA, USA). 
Ontology-based  analyses were performed using  the Panther 
database  (http://www.pantherdb.org).
Reverse transcription and real-time PCR
Reverse transcription (RT) was carried out according to the 
instructions  in  the  ImProm-II
TM  reverse  transcription  system 
(Promega, Madison, WI, USA). In brief, 1 μg of total RNA 
was reverse-transcribed in a total volume of 20 μl using an 
oligo-dT primer. The RT reaction was performed at 25
oC for 
5 min, 42
oC for 1 hr, and 70
oC for 15 min. One μl of cDNA 
was used as a template for real-time PCR in a 25 μl reaction 
mixture,  including  0.75  U  of  GoTaq  DNA  polymerase 
(Promega), 5μl of 5X buffer, 0.2 mm of dN TP (Promega), 
2.5μl of 3000X SYBR Green I (BMA, Rockland, ME, USA), 
and 10 pM of each primer. Oligonucleotide primers for re-
al-time PCR were prepared using Primer 3 software (White-
head Institute/MIT Center for Genomes Research, Cambridge, 
MA;  http://www.bioneer.co.kr/cgi-bin/primer/primer3.cgi). 
Information  and  sequences  of  primers  of  the  steroidogenic 
enzymes tested in the present study are summarized in Table 
I. The PCR program used an initial step of 95
oC for 5 min 
for  pre-denaturation,  followed  by  denaturation  at  94
oC,  an-
nealing, and extension at 72
oC using the PTC-200 Chromo 4 
real-time system (Bio-Rad Laboratories, Hercules, CA, USA). 
The  final  extension  was  carried  out  for  10  min  at  72
oC. 
Beta-actin was included as an internal PCR control. For quan-
tification of real-time PCR results, the relative standard curve 
method was used to obtain quantitative values. Each sample 
was replicated three-to-four times, and the normalized mean 
value  to  beta-actin  was  used  for  final  comparison. 
Real-time PCR data presentation and statistical 
analysis
Data  for  mRNA  abundance  were  expressed  relative  to  the 
control and CIA groups on days 4 and 9. In the figures, data 
are presented as the mean±standard error. Comparisons be-
tween CIA and controls were performed using one-way anal-
ysis of variance, followed by the Mann-Whitney U test, using 
SPSS software (SPSS Inc., Chicago, IL, USA). In all cases, a 
p＜0.05  was  considered  statistically  significant.
Histology
At  the  end of  each experiment,  the  knee  joints were  fixed 
in 4% formalin for 2 days, decalcified in EDTA for 3 weeks, 
then embedded in paraffin. From the paraffin-embedded tis-Gene Expression Profile of CIA
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Table II. List of immune-mediated genes that were up- or 
down-regulated in each organ of CIA compared to control groups
Gene
Thymus Blood Synovium
4 days 9 days 4 days 9 days 4 days 9 days
  Itk 1.00 1.01 －1.43 －1.37 －7.56 －2.68
  Il1f8 1.09 －1.00 2.11 1.34 1.28 1.86
  CD3ζ－ 1.16 －1.14 －1.55 －1.28 －8.31 －3.43
  CD6 －1.16 －1.03 －1.24 －1.08 －2.05 －1.20
  CD3ε 1.06 1.04 －1.13 －1.11 －6.74 －2.58
  CD3δ－ 1.02 1.10 －1.25 －1.05 －13.19 －5.18
  CD8β－ 1.08 －1.09 1.00 1.05 －6.69 －2.73
  CD8α－ 1.09 －1.15 －1.25 －1.18 －10.96 －4.45
The data shown here are the ratio of gene expression of the 
CIA-to-control group in each organ.
Figure 1. Number of immune-related genes differentially-expressed in 
the early phase of CIA. RNA samples were collected from the thymus,
blood, and synovium of the CIA and control groups on days 4 and 
9 after the 1st immunization. A RatRef-12 expression beadchip with
21,910 gene specificities was used to define the gene expression 
profile in CIA and control rats. Only immune-related genes 
differentially-expressed between the CIA and control groups are 
shown here. Most genes differentially-expressed in CIA were shown 
in the synovium on days 4 and 9 (dotted bar), whereas 1 gene in 
the blood was shown on day 4 (white bar), and no genes were shown 
in the thymus (black bar).
sue blocks, 2-μm sections were cut and stained with haema-
toxylin-eosin  for  histologic  analysis. 
RESULTS
A great number of genes were significantly 
modulated during the initiation stage of CIA
To define the gene expression profile in the initiation stages 
o f  C I A ,  w e  u s e d  a  e x p r e s s i o n  c h i p  w i t h  2 1 , 9 1 0  g e n e  
specificities.  First,  gene  expression  was  compared  between 
the  CIA  and  control  groups  on  days  4  and  9  after  the  1st 
immunization. We observed 1,243 genes were expressed dif-
ferentially in CIA on day 4 than on day 9, which could be 
attributable to a biological process or molecular function (Fig. 
1). Table II shows the list of up- or down-regulated genes 
according  to  the  organ  in  which  they  were  differ-
entially-expressed. We found that the synovium was the or-
gan in which most genes were differentially-expressed, and 
only  one  gene,  Il1f8,  was  differentially-expressed  in  the 
blood. No gene was differentially-expressed in the thymus. 
Differential expression of genes encoding T-cell 
receptors (TCRs) in arthritic synovial tissue of CIA
Since we founded on T cell associated genes, we analyzed 
genes related to TCR/CD3 complex, including CD3δ, CD3ε, 
and  CD3ζ.  Interestingly,  most  genes  encoding  TCR  were 
down-regulated in CIA (Fig. 2A). Day 4 showed a greater dif-
ference  in  gene  expression  than  day  9  between  CIA  and 
controls.  Next,  we  analyzed  which  organ  showed  differ-
entially expressed genes. The synovium was the only organ 
in which the genes were differentially expressed between CIA 
and control groups, whereas no difference was found in the 
thymus  and  blood.
    Next,  we  analyzed  gene  expressions  of  CD4  and  CD8 
which are another T cell surface molecules that play an addi-
tional role in T cell recognition (15). The expression of the 
CD8α and CD8β genes were reduced significantly in CIA, 
howerer the CD4 gene was expressed similarly between CIA 
and control groups (Fig. 2B). To validate our microarray find-
i n g s ,  w e  p e r f o r m e d  r e a l - t i m e  R T - P C R  o n  t h e  g e n e s  o f  
TCR/CD3 and T cell co-receptors using independent animals. 
The expression of CD3δ, CD3ε, CD3ζ, CD8α, and CD8β, 
as revealed by RT-PCR, was in agreement with the microarray 
data  (Fig.  3). 
Gene expression profile in rats immunized only with 
CII or adjuvant
We next determined whether the differential expression of T 
cell-mediated  genes  was  more  affected  by  CII  or  adjuvant. 
We compared four groups of rats, including rats immunized 
both with IFA and CII (CIA), rats immunized only with IFA 
(rIFA), rats immunized only with CII (rCII), and unimmunized 
rats. Asshown in the previous analysis between the CIA and 
control groups, gene expression profile showed greater differ-
e n c e  o n  d a y  4  t h a n  d a y  9  b o t h  i n  r C I I  a n d  r I F A  ( F i g .  4 ) .  Gene Expression Profile of CIA
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Figure 2. The ratio of TCR-related gene expression of the CIA-to-control group in each organ in the initiation phase of CIA. TCR-related gene
expression was compared between the CIA and control groups. The data shown here are the ratio of gene expression of the CIA-to-control
group in each organ. (A) CD3 complex gene expression. CD3δ, CD3ε, and CD3ζ gene expression was down-regulated in the synovium of
CIA, with no differences in the thymus and blood. (B) CD4 and CD8 gene expression. CD8α and CD8β gene expression was down-regulated
in the synovium of CIA, with no difference in the thymus and blood. No difference in CD4 gene expression existed between the CIA and
control groups in the synovium, thymus, or blood.
(A) (B) (C)
(D) (E)
Figure 3. Validation of the CD3 complex and CD8 gene expression in CIA and control groups. RT-PCR was performed using SYBR and a specific
primer set for (A) CD3δ, (B) CD3ε, (C) CD3ζ, (D) CD8α, and (E) CD8β. The RNA samples are independent of the samples used for microarray
analysis. Data are expressed as the mean±SD. *p＜0.05 by the Mann-Whitney U test.Gene Expression Profile of CIA
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Figure 4. Number of genes differentially-expressed in CIA and rats immunized only with CII or adjuvant. To define the gene expression profile
in the initiation stages of CIA, we used a RatRef-12 expression beadchip (Illumina Inc., San Diego, CA, USA) with 21,910 gene specificities,
and compared the following 3 groups of rats with the control group: (A) IFA/CII immunized (CIA), (B) CII immunized, and (C) IFA (MDP). Samples
were collected from the thymus (black bar), blood (white bar), and synovium (dotted bar).
Table III. List of TCR-mediated genes that were up- or 
down-regulated in the synovium of CIA compared to control 
depending on various inducers
Gene
Fold change (treatment/control) 
CII IFA CIA
4 day 9 day 4 day 9 day 4 day 9 day
  CD3δ－ 1.89 1.53 －21.84 －3.19 －14.84 －5.48
  CD3ε －3.17 －1.35 －6.03 －1.86 －7.68 －2.77
  CD3ζ－ 1.61 1.20 －10.59 －2.59 －9.46 －3.72
  CD4 －4.13 －1.46 －2.44 －1.88 －1.63 1.02
  CD8α －2.46 －1.09 －21.48 －4.03 －11.96 －4.59
  CD8β－ 2.31 －1.06 －9.73 －2.92 －7.60 －2.93
The data shown here are the ratio of gene expression of the 
immunized rat-to-control group in each organ.
CIA: collagen induced arthritis, CII: native type-II collagen, IFA: 
incomplete Freund adjuvant.
Most  genes  were  differentially  expressed  in  the  synovium, 
whereas the thymus showed only one gene differentially-ex-
pressed  in  rCII  on  day  9.
  Interestingly, the synovium of CII showed down-regulation 
of one CD3 complex gene, CD3ε, whereas the synovium of 
IFA showed down-regulation of more genes including CD3δ, 
CD3ε, and CD3ζ on day 4, as shown in CIA (Table III). 
Furthermore, the difference of gene expression compared to 
controls was greater in rIFA than in CIA. In terms of T cell 
co-receptor, even though both the synovium of rCII and rIFA 
showed down-regulation of CD8α and CD8β, a greater dif-
ference in gene expression was shown in rIFA compared to 
rCII or CIA. CD4 gene expression was decreased in rIFA com-
p a r e d  t o  r C I I ,  w h i c h  w a s  n o t  s h o w n  i n  C I A .  
    In  addition,  other  genes  were  expressed  differentially  on 
rCII or rIFA, which was not differentially expressed in CIA. 
The blood of rCII revealed up-regulation of Btk, Tmpo, and 
Tapbp  on  day  4,  and  up-regulation  of  IL9r  and  Ciita,  and 
down-regulation of Ctss and Sh2d2a on day 9. The synovium 
of rCII showed up-regulation of Sqstm1 and down-regulation 
of  Tapbp,  Hla-dma,  and  Nfatc3  (Table  IV). 
    The blood of rIFA showed up-regulation of IL1f8, Adora2a, 
Tnfrsf1a, and Ifi35, in addition to that showed the genes that 
showed increased expression in rCII on day 4. The Sh2d2a, 
Ctse,  Gzmk,  and  Itk  were  down  regulated  in  the  blood  of 
rIFA, and the synovium of  rIFA showed down-regulation of 
Sh2d2a,  Ctse,  Nfatc3,  Sla,  and  Itk  on  day  4  (Table  V).
Pathologic analysis of synovium in CIA rats and 
controls
We  also  examined  synovia  pathologically  at  the  initiation 
time, but there were no differences among the four groups, 
including CIA, rIFA, rCII, and unimmunized. These results in-
dicated that there were changes at the molecular level before 
histologic  changes  began,  including  synovial  hypertrophy, 
pannus  formation,  cartilage  destruction,  and  bone  erosion.Gene Expression Profile of CIA
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Table IV. List of immune-mediated genes that were up- or 
down-regulated in each organ of rats immunized only with CII 
compared to control groups
Gene
Thymus Blood Synovium
D a y  4D a y  9D a y  4D a y  9D a y  4D a y  9
  Btk －1.21 －1.21 2.06 －1.29 －1.64 －1.66
  Tmpo 1.17 1.77 2.25 1.98 1.47 1.17
  Tapbp －1.13 1.05 2.49 1.18 －2.39 －1.09
  CD3δ 1.05 1.04 －2.26 －1.05 －1.89 1.53
  Sqstm2 1.00 －1.02 －1.08 1.21 2.21 －1.04
  Sqstm1 1.20 －1.19 1.78 －1.30 －2.40 1.15
  Hla-dma －1.04 －1.43 －1.09 －1.50 －3.05 －1.33
  CD4 1.14 1.33 1.19 －1.12 －4.13 －1.46
  CD8β 1.23 －1.16 －1.05 1.52 －2.31 －1.06
  CD3ε 1.15 1.05 1.11 1.25 －3.17 －1.35
  CD8α－ 1.30 －1.08 －1.46 1.03 －2.46 －1.09
  Il9r 1.46 1.55 1.38 2.14 1.17 1.13
  Ctss －1.63 －2.15 －1.16 －2.25 1.08 －1.52
  Ciita 1.15 1.15 1.69 2.19 1.23 －1.24
  Sh2d2a －1.12 －1.28 －1.49 －2.04 －1.33 －1.04
The data shown here are the ratio of gene expression of the 
immunized rat-to-control group in each organ.
Table V. List of immune-mediated genes that were up- or 
down-regulated in each organ of rats immunized only with 
adjuvant compared to control groups
Gene
Thymus Blood Synovium
D a y  4D a y  9D a y  4D a y  9D a y  4D a y  9
  Il1f8 1.42 1.00 2.87 2.21 －1.01 1.02
  Adora2a 1.55 1.27 2.49 2.05 1.35 1.51
  Btk －1.03 －1.36 2.20 －1.02 －1.62 －1.46
  Tnfrsf1a －1.17 1.16 2.70 2.20 1.14 1.43
  Tmpo 1.25 1.29 2.30 1.98 －1.02 1.24
  Tapbp －1.20 －1.08 2.16 －1.07 －1.12 －1.13
  Ifi35 －1.13 －1.03 2.26 1.94 －1.02 1.05
  Sqstm1 1.23 1.42 2.00 －1.04 1.60 1.30
  Sh2d2a －1.19 －1.02 －2.35 －2.25 －2.15 －1.34
  Ctse －1.27 1.00 －2.04 －1.73 －2.61 －1.74
  CD8α－ 1.38 －1.24 －2.20 －1.24 －21.48 －4.03
  CD3δ 1.03 1.11 －2.21 －1.31 －21.84 －3.19
  Itk －1.05 1.33 －2.70 －2.16 －9.22 －2.26
  Gzmk －1.09 1.07 －3.25 1.53 －1.01 －1.00
  CD3ζ－ 1.00 1.08 －2.21 －1.39 －10.59 －2.59
  Nfatc3 1.02 1.09 －1.82 －1.30 －3.04 －1.42
  CD4 －1.05 1.15 1.58 1.63 －2.44 －1.88
  Sla 1.28 1.32 －1.01 1.11 －2.01 －1.46
  CD8β 1.07 1.03 －1.04 1.45 －9.73 －2.92
  CD3ε 1.09 1.11 －1.41 －1.23 －6.03 －1.86
The data shown here are the ratio of gene expression of the 
immunized rat-to-control group in each organ. DISCUSSION
During the 1990s, the widely accepted concept of cytokine 
networks  perpetuating  disease,  with  tumor  necrosis  factor 
(TNF)-α assuming a hierarchical role (16), was supported by 
the  success  of  TNF-α-blocking  treatment  in  RA  (17,18). 
However, the lack of universal benefit from TNF-α-blocking 
therapy (19) has focused attention to alternative upstream im-
munologic mediators. The central questions relate to the fac-
tors  that  serve  to  initiate,  amplify,  and  mature  the  immune 
responses in RA. Gene expression profiles at different stages 
of  CIA  have  been  reported  previously  (20).  However,  it  is 
d i f f i c u l t  t o  d e t e r m i n e  t h e  c a u s a l  g e n e s  i n  t h o s e  s t u d i e s  b e-
cause  too  many  genes  were  already  expressed  when  in-
flammatory features developed. Thus, we were interested in 
gene expression profiles at an earlier time point, such as im-
mediately  after  the  1st  immunization.  Especially,  we  inves-
tigated focused on T cell immunity-related genes because sev-
eral observations over the years supported a fundamental role 
f o r  T  c e l l s  i n  R A  ( 2 1 , 2 2 ) .  R A  s y n o v i u m  c o n t a i n s  a  r i c h  i n-
filtrate of activated CD4＋ cells and MHC class II molecules 
(23)  with  a  correlation  between  the  number  of  synovial  T 
cells and the severity of joint damage (24). In addition, we 
considered which organs would be involved in dysregulation 
of T cell-mediated immunity in RA, because there were sev-
eral  lines  of  evidence  that  thymic  abnormalities  were  asso-
ciated with the pathogenesis of RA. The identification of other 
joint-specific antigens, such as gp-39 in thymic Hassallʼs cor-
puscles and medullary epithelial cells, provide new insight in-
to the mechanisms of RA pathogenesis and may lead to more 
specific  and  physiologic  methods  of  immune-modulation 
(25). Therefore, we investigated central immune organ, even 
thought thymus would not be affected by immunization. We 
determined the  genome-wide expression  profile of  the  thy-
mus  in  addition  to  synovial  joints  and  peripheral  blood. 
    Our original hypothesis was that T cells could escape neg-
ative selection because intracellular signal transduction of thy-
mocytes was dysregulated. The TCR/CD3 complex is one of 
the  most  intricate  membrane  receptor  structures  because  it 
consists of six distinct chains (26,27). The clonotypic α and 
β chains of the TCR are responsible for recognizing antigen 
embedded  in  the  MHC  molecule  present  on  the  surface  of Gene Expression Profile of CIA
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antigen-presenting cells (APCs). The remaining chains, collec-
tively called the CD3 complex, include the CD3-γ, -δ, -ε, 
and  -ζ  chains  (26).  T  cells  implicated  in  chronic  in-
f l a m m a t o r y  d i s e a s e s ,  s u c h  a s  R A ,  r e s p o n d  w e a k l y  w h e n  
stimulated in vitro with mitogen or antigen (28). Decreased 
expression of the TCR-associated CD3ζ chain has been sug-
gested, but the mechanism underlying this hypo-responsive-
ness is unclear (29-33). Therefore, we investigated when TCR 
started to be decreased in the course of CIA development. 
We focused on the initiation time before looking at the whole 
picture  through  the  total  period  of  CIA  development. 
    In  our  study,  TCR  down-regulation  occurred  at  an  early 
phase of CIA, and most genes expressed differentially were 
found  in  the  synovium,  not  in  the  thymus  and  blood. 
Synovium tissue contains heterogeneous population of stro-
mal cells and immune cells. Especially, there was definitely 
higher number of lymphocyte infiltrated in the synovium of 
C I A  t h a n  c o n t r o l .  T h e r e f o r e ,  t h e  e x p r e s s i o n  o f  T  c e l l  r e -
ceptors should be increase in CIA. However, we found the 
opposite result which is consistent with the result of former 
studies in which TCR-associated CD3ζ chain is decreased in 
CIA and RA (31,33). It was leading to the hypothesis that the 
synovium might play a pathologic role on T cells which re-
mains  to  be  clarified.
    It has been reported that there is a correlation between the 
levels of TNF-α produced after anti-CD3 or PHA stimulation 
and  the  expression  of  CD3ζ ( 34 ).  Ho w ev e r,  in  o ur  st ud y , 
TNF-α had not been expressed until day 9. Therefore, we 
could  guess  that  TNF-α w a s  n o t  i n v o l v e d  i n  C D 3 ζ 
down-regulation,  which  remains  to  be  clarified. 
    Another T cell surface molecules, CD4 and CD8, play a crit-
ical  role  in  T  cell  recognition  and  activation  by  binding  to 
their respective class II and I MHC ligands on APCs. In addi-
tion, CD4 and CD8 are also involved in post-binding events 
that lead to CTL activation and subsequent lysis of the target 
cells  (35).
    CD8 T cells are part of the T cell pool infiltrating the syno-
vium in RA. However, the role of CD8 T cells in the patho-
genesis  of  RA  has  not  been  fully  delineated.  In  our  study, 
the gene expression of CD8 receptors also decreased in the 
CIA  group compared to the control  group. Therefore, with 
down-regulation of the CD3 complex and CD8 receptors, T 
cells  would  be  severely  defective  in  activation. 
    Next, we questioned which factor would play a greater role 
in the down-regulation of TCR genes. The synovium from the 
rats immunized only with CII showed down-regulation of on-
ly one gene, CD3ε, whereas the synovium in the rats immu-
nized only with adjuvant showed down-regulation of CD3δ, 
CD3ε,  and  CD3ζ,  which  showed  a  greater  difference  of 
gene expression compared to CII-immunized rats or CIA. T 
cell co-receptors, CD8α, and CD8β, which were down-regu-
lated in CIA, showed a greater difference of gene expression 
in adjuvant-immunized rats compared to CII-immunized rats 
o r  C I A .  C D 4  g e n e  e x p r e s s i o n  w a s  d e c r e a s e d  b o t h  i n  a d -
juvant-immunized rats and CII-immunized rats, which was not 
shown in CIA. Taken together, adjuvant played a greater role 
in the down-regulation of the CD3 complex and co-receptors. 
Therefore, infectious triggers might play an important role in 
the  down-regulation  of  the  TCR  gene  CIA.
    Furthermore, more genes were shown to be expressed dif-
ferentially when we immunized rats with CII or adjuvant com-
pared to the CIA. Even the blood in the rats immunized with 
CII  only  and  with  adjuvant  only  revealed  another  genes 
which  were  expressed  differentially,  including  Btk,  Tmpo, 
T a p b p ,  I L 9 r ,  C i i t a ,  C t s s ,  S h 2 d 2 a ,  S q s t m 1 ,  T a p b p ,  H l a - d m a ,  
Nfatc3, IL1f8, Adora2a, Tnfrsf1a, Ifi35, Ctse, Gzmk, and Itk. 
The function of those genes in the pathogenesis of CIA re-
mains  to  be  elucidated.
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